Cover Image
市場調查報告書

肝癌:流行病學、病患人數的市場預測、治療流程、上市藥及開發平台藥物分析

Hepatocellular cancer: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365187
出版日期 內容資訊 英文 216 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
肝癌:流行病學、病患人數的市場預測、治療流程、上市藥及開發平台藥物分析 Hepatocellular cancer: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年04月01日 內容資訊: 英文 216 Pages
簡介

Nexavar的成功刺激了新標靶藥物開發,這些認證,進一步促進肝癌市場。

本報告提供肝癌治療藥趨勢調查,市場定義和概要,疾病定義與診斷,目前治療選擇,處方趨勢,已上市產品簡介,開發後期的開發平台趨勢等彙整資料。

預測:美國、日本、EU的肝癌治療藥

  • 摘要整理
  • 市場概要、趨勢
  • 調查手法、市場定義
  • ADI-PEG 20 (PEG-arginine deiminase)
  • Cometriq
  • Nexavar (Sorafenib)
  • Ramucirumab
  • Stivarga (Regorafenib)
  • tivantinib (ARQ 197)
  • TS-1 (gimeracil/oteracil potassium/tegafur)
  • 一次調查技術

治療方法

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷
  • 各國治療樹
  • 患者區分
  • 目前治療選擇
  • 處方趨勢
  • 未來的治療的變化

流行病學:美國、日本、歐盟5國的肝癌

  • 摘要整理
  • 疾病的背景
  • 資訊來源、分析方法
  • 預測
  • 流行病學者的見解
  • 優勢、規定

上市藥:肝癌

  • 摘要整理
  • 產品概要
  • 產品簡介:Nexavar

開發平台:肝癌

  • 摘要整理
  • 臨床實驗平台概要
  • 產品簡介 (開發後期):ADI-PEG 20
  • 產品簡介 (開發後期):Cometriq
  • 產品簡介 (開發後期):Cyramza
  • 產品簡介 (開發後期):Lenvima
  • 產品簡介 (開發後期):Stivarga
  • 產品簡介 (開發後期):Stivarga
  • 產品簡介 (開發後期):tivantinib

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5611

The success of Nexavar has boosted the development of new targeted therapies, approvals of which will drive the growth of the hepatocellular cancer market.

This report addresses the following questions:

  • Which products will drive the growth of the hepatocellular cancer market?
  • What is the commercial potential for each drug in the late-stage pipeline for hepatocellular cancer?
  • Which geographic markets have the largest populations of hepatocellular cancer patients and how does this impact each market's value?
  • What are the most common treatment settings within hepatocellular cancer being targeted by drug developers?
  • Which pipeline products will actively compete with each other once they reach the market and how will they impact currently approved drugs?

TABLE OF CONTENTS

FORECAST: HEPATOCELLULAR CANCER IN THE US, JAPAN, AND EU

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Methodology and Market Definition
  • 4. ADI-PEG 20 (PEG-arginine deiminase)
  • 5. Cometriq
  • 7. Nexavar (sorafenib)
  • 8. Ramucirumab
  • 9. Stivarga (regorafenib)
  • 10. tivantinib (ARQ 197)
  • 11. TS-1 (gimeracil/oteracil potassium/tegafur)
  • 12. Primary Research Methodology

TREATMENT: HEPATOCELLULAR CANCER

  • 13. Executive Summary
  • 14. Primary Research Methodology
  • 15. Disease Definition and Diagnosis
  • 16. Country Treatment Trees
  • 17. Patient Segmentation
  • 18. Current Treatment Options
  • 19. Prescribing Trends
  • 20. Future Changes in Therapy

EPIDEMIOLOGY: HEPATOCELLULAR CANCER IN THE US, JAPAN, AND 5EU

  • 21. Executive Summary
  • 22. Disease Background
  • 23. Sources and Methodology
  • 24. Forecast
  • 25. Epidemiologist Insight
  • 26. Strengths and Limitations

MARKETED DRUGS: HEPATOCELLULAR CANCER

  • 27. Executive Summary
  • 28. Product Overview
  • 29. Product profile: Nexavar

PIPELINE: HEPATOCELLULAR CANCER

  • 30. Executive Summary
  • 31. Clinical Pipeline Overview
  • 32. Target Product Profile
  • 33. Product profile (late stage): ADI-PEG 20
  • 34. Product profile (late stage): Cometriq
  • 35. Product profile (late stage): Cyramza
  • 36. Product profile (late stage): Lenvima
  • 37. Product profile (late stage): Stivarga
  • 38. Product profile (late stage): peretinoin
  • 39. Product profile (late stage): tivantinib
Back to Top